Paradigm Therapeutics Named Prix Galien Finalist
The Mount Pleasant biotech firm earned a finalist spot for the 2026 Prix Galien USA Best Start-Up Award.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should the public place higher priority on supporting new companies developing treatments for rare diseases?
Mount Pleasant-based Paradigm Therapeutics has been named a finalist for the 2026 Prix Galien USA Best Start-Up Award. This marks the second consecutive year the company has received a nomination for the prestigious honor.
Why it matters
The recognition follows significant regulatory milestones for the company, including FDA Breakthrough Therapy designation for its primary candidate, SD-101. Success in these clinical programs could lead to the receipt of a Priority Review Voucher upon eventual regulatory approval.
Clinical trials for SD-101 (Zorblesia) included 217 pediatric and adult patients across Simplex, Dystrophic, and Junctional EB subtypes. The treatment was applied daily over the entire body for three months in completed studies.
The players
Paradigm Therapeutics
A biotechnology company headquartered in Mount Pleasant, South Carolina, focused on developing new therapies for rare skin conditions.
The Galien Foundation
The organization responsible for managing the selection process and hosting the Prix Galien USA Awards ceremony.
The details
The company’s drug candidate, SD-101, has received Rare Pediatric Disease and Orphan Drug designations from the FDA, alongside Orphan Drug designation from the European Commission. The firm is currently conducting a confirmatory two-month study involving pediatric patients as young as 28 days.
Timeline
Paradigm Therapeutics received a previous nomination in 2025.
The nomination for the 2026 award was announced on October 14, 2026.
The 2026 Prix Galien USA Awards ceremony occurs on October 29, 2026.
The Big Picture
This nomination marks a continuation of the firm's industry standing following its appearance in the 2025 Prix Galien USA Best Start-Up Award nominations. The firm remains a key player in the biotech sector by extending its track record of recognition within the Galien Foundation framework.
The potential approval of SD-101 could expand available treatment options for patients suffering from rare skin subtypes. Future regulatory updates will determine the timeline for the drug's availability to the public.
The takeaway
The firm’s consistent recognition highlights the clinical progress of its lead candidate for treating various EB subtypes. Continued clinical confirmatory studies will be essential for the company to move closer to full regulatory approval.
What happens next
The 2026 Prix Galien USA Awards ceremony is scheduled to take place on October 29, 2026, where the final winners will be announced.
Further reading
Learn more about the latest industry developments in Biotech.
More information
Access additional clinical documentation on the Paradigm Therapeutics clinical therapy information portal.
Live Poll
Should the public place higher priority on supporting new companies developing treatments for rare diseases?
